Life science and clinical research company Bruker Corp BRKR.O shares down about 5.9% at $35.75 in early trading
Lowers FY 2025 adj. EPS between $1.95 - $2.05 from prior expectations of $2.40 - $2.48
Trims FY 2025 revenue outlook to $3.43 bln - $3.50 bln from previous target of $3.48 bln - $3.44 bln
Expanded cost savings initiative expects to cut annual costs by $100-$120 mln in FY 2026
Misses Q2 revenue and adj. profit estimates, hurt by challenging demand conditions in the U.S. academic market
"Tariffs and stiff currency headwind could not be compensated by mitigating price, supply chain and cost actions in Q2." - CEO Laukien
Stocks down 35.19% YTD